Document:

Exhibit

EXHIBIT 10.3

September 19, 2016

Alex Pease
[ADDRESS]

Dear Alex:

You have made a favorable impression on everyone you have met during our interview process.  Your depth of experience, business competence and leadership capabilities are characteristics we value at Snyder’s-Lance.  Therefore we are excited to offer you the position of Executive Vice President and Chief Financial Officer reporting to Carl E. Lee, Jr., Chief Executive Officer.  Below are the details of your employment offer: 

Start Date: November 1, 2016 (or earlier)

Base Compensation: Annualized base salary of $535,000 subject to applicable withholdings. Eligibility for an annual performance review and merit increase beginning in January 2018.

Annual Incentive Plan (AIP) Participation:  AIP target of 75% of base salary.  Eligibility for participation in the 2016 performance year on a pro-rated basis, however guaranteed at a minimum $100,000.  

Long Term Incentive Plan Participation: First annual grant beginning in quarter one, 2017 at $700,000.  Components of the plan design include restricted stock, stock options and performance shares.  Further details of the plan are specified in the 2016 Key Employee Incentive Plan document which will be provided to you upon grant date. 

Special One Time Sign On: 
		
	•
	$100,000 cash payment (less applicable taxes and deductions) to be paid within 30 days of start date

		
	•
	Sign on equity award in November 2016, with a value of $300,000 in the form of restricted stock units and non-qualified stock options.

		
	•
	$450,000 cash payment (less applicable taxes and deductions) to be paid in June 2017. 

Benefits and additional details:
		
	•
	Eligibility to participate in all of our Company sponsored benefit and retirement plans. 

		
	•
	Four weeks of paid vacation effective in 2017.

		
	•
	Access to a Snyder’s-Lance Inc. corporate membership at Ballantyne Country Club.  You will be responsible for all charges as well as monthly dues and any assessments.

This offer is contingent upon successful completion of our standard pre-employment drug screen and background investigation.  After receiving your signed acceptance, the necessary forms to be completed to initiate this process will be emailed to you.

We remind you that you will be an “at-will” employee, meaning that you or Snyder’s-Lance may terminate the employment at any time for any reason not prohibited by law with or without prior notice. Nothing in this offer letter alters your status as an “at-will” employee. Further, nothing in this offer is intended to create a contract for employment or guarantee of continued employment with Snyder’s-Lance. 

Alex, it is an exciting time for our organization, and we are very confident that you will help us achieve our growth goals.  We have all enjoyed getting to know you, and we are very excited to have you join our team. 

Your acceptance of this offer may be communicated by signing below and forwarding a copy to my attention by 5:00 pm September 20 2016.  After this time, this offer will expire. Please scan and email back to me at xxx@xxx.com

If you have any questions, please do not hesitate to contact me at (xxx) xxx-xxxx.

            

Sincerely,

	
					
	Andrea Frohning
	 
	 
	 
	 

	Chief Human Resources Officer
	 
	 
	 
	 

Acknowledgement of Acceptance:

	
					
	/s/ Alex Pease
	 
	 
	 
	September 19, 2016

	Alex Pease
	 
	 
	 
	Datefgen-ex1026_175.htm

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxix)

Amendment No. 27 to the Process Development and Clinical Supply Agreement

This Amendment No. 27 (the “27th Amendment”), effective as of the date of the last signature (the “26th Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and  on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 21, 2013, Amendment No. 11, effective as of July 9, 2013, Amendment No. 12, effective as of August 01, 2013 and subsequently assigned by BI Pharma to BI, Amendment No. 13, effective as of March 06, 2014, Amendment No. 14, effective as of February 05, 2014, Amendment No. 15, effective as of October 20, 2014, Amendment No. 16, effective as of December 08, 2014, Amendment No. 17, effective as of December 08, 2014, Amendment No. 18, effective as of February 15, 2015, Amendment No. 19, effective as of March 01, 2015, Amendment No. 20, effective as of June 01, 2015, Amendment No. 21, effective as of May 29, 2015, Amendment No. 22, effective as of  April 14, 2016, Amendment No. 23, effective as of September 01, 2015, Amendment No. 24, effective as of September 15, 2015, Amendment No. 25, effective as of September 15, 2015, Amendment No. 26, effective as of June 30, 2016 (hereinafter together the “Supply Agreement”). BI and FIBROGEN shall be referred to individually herein as a “Party”, and collectively as the “Parties”. 

Whereas, FibroGen wishes BI to [*] in compliance with the terms of the Supply Agreement as set forth in and as amended by this 27th Amendment. The activities hereunder will be performed by BI Pharma on behalf of BI. 

Now, Therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

	
 
	
(1)
	
Unless otherwise defined herein, all capitalized terms and phrases used in this 27th Amendment shall have the meaning ascribed to them in the Supply Agreement.

	
 
	
(2)
	
The Parties agree that pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[*], Version of June 8, 2016”, attached hereto as Exhibit A, is hereby added as an amendment to Appendix 2 to the Supply Agreement. Pursuant thereto BI in accordance with the Supply Agreement, [*] (defined in the Supply Agreement).

	
 
	
(3)
	
This 27th Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this 27th Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly superseded by this 27th Amendment. 

	
 
	
(4)
	
This 27th Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent.

 

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxix)

IN WITNESS WHEREOF, the Parties have executed this 27th Amendment to the Supply Agreement as of the 27th  Amendment Effective Date.

Biberach, July 20, 2016

Boehringer Ingelheim Biopharmaceuticals GmbH

	
ppa.
	
 
	
ppa.

 

	
[*]
	
 
	
[*]

	
[*]
	
 
	
[*]

	
VP Business & Contracts
	
 
	
Head of Corporate Legal Biopharmaceuticals

San Francisco, July 25, 2016

FibroGen, Inc

 

	
/s/ Michael Lowenstein
	
 
	
/s/ David Dimmick

	
Name...Michael Lowenstein
	
 
	
Name...David Dimmick

	
Title      Chief Legal Counsel
	
 
	
Title......VP Quality

 

 

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxix)

Exhibit A

Work Scope

[*] 

(Version of June 8, 2016) 

[*]fgen-ex1026_174.htm

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxx)

Amendment No. 28 to the Process Development and Clinical Supply Agreement

This Amendment No. 28 (the “28th Amendment”), effective as of the date of the last signature (the “28th Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and  on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 21, 2013, Amendment No. 11, effective as of July 9, 2013, Amendment No. 12, effective as of August 01, 2013 and subsequently assigned by BI Pharma to BI, Amendment No. 13, effective as of March 06, 2014, Amendment No. 14, effective as of February 05, 2014, Amendment No. 15, effective as of October 20, 2014, Amendment No. 16, effective as of December 08, 2014, Amendment No. 17, effective as of December 08, 2014, Amendment No. 18, effective as of February 15, 2015, Amendment No. 19, effective as of March 01, 2015, Amendment No. 20, effective as of June 01, 2015, Amendment No. 21, effective as of May 29, 2015, Amendment No. 22, effective as of  April 14, 2016, Amendment No. 23, effective as of September 01, 2015, Amendment No. 24, effective as of September 15, 2015, Amendment No. 25, effective as of September 15, 2015, Amendment No. 26, effective as of June 30, 2016 (hereinafter together the “Supply Agreement”), Amendment No. 27, effective as of July 25, 2016 (hereinafter together the “Supply Agreement”). BI and FIBROGEN shall be referred to individually herein as a “Party”, and collectively as the “Parties”. 

Whereas, FibroGen wishes BI to [*] BI in compliance with the terms of the Supply Agreement as set forth in and as amended by this 28th Amendment. The activities hereunder will be performed by BI Pharma on behalf of BI. 

Now, Therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

	
 
	
(1)
	
Unless otherwise defined herein, all capitalized terms and phrases used in this 28th Amendment shall have the meaning ascribed to them in the Supply Agreement.

	
 
	
(2)
	
The Parties agree that pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[*], Version of August 31, 2016”, attached hereto as Exhibit A, is hereby added as an amendment to Appendix 2 to the Supply Agreement. Pursuant thereto BI in accordance with the Supply Agreement, provide [*] (defined in the Supply Agreement).

	
 
	
(3)
	
This 28th Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this 28th Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly superseded by this 28th Amendment. 

	
 
	
(4)
	
This 28th Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent.

 

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxx)

IN WITNESS WHEREOF, the Parties have executed this 28th Amendment to the Supply Agreement as of the 28th  Amendment Effective Date.

Biberach, September 22, 2016

Boehringer Ingelheim Biopharmaceuticals GmbH

	
ppa.
	
 
	
ppa.

 

	
[*]
	
 
	
[*]

	
[*]
	
 
	
[*]

	
SVP Corp. Div. Biopharmaceuticals
	
 
	
Head of Corporate Legal Biopharmaceuticals

San Francisco, September 15, 2016

FibroGen, Inc

 

	
/s/ David Dimmick
	
 
	
 

	
Name... David Dimmick
	
 
	
 

	
Title... VP Quality
	
 
	
 

 

 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934, as amended.

Exhibit 10.26(xxx)

Exhibit A

Work Scope

[*]

(Version of August 31, 2016) 

[*]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]